EyePoint Pharmaceuticals

Press Releases

EyePoint Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress
May 08, 2019
- YUTIQ™ and DEXYCU™ commercially launched in 1Q2019 – - YUTIQ recommended for specific J-code by Centers for Medicare & Medicaid Services - - Debt refinancing and equity public offering generated net proceeds of approximately $30.0 million - - Company optimistic that current cash balance and cash
EyePoint Pharmaceuticals Presents Positive YUTIQ™ 36-month Follow-up Phase 3 Data at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 01, 2019
  –  36-month data showed a uveitis eye flare recurrence rate of 56.3% in YUTIQ-treated eyes vs. 92.9% in sham eyes -              – Durability of 36-month data and safety support long-term efficacy of YUTIQ - WATERTOWN, Mass. , May 01, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals Announces First Quarter 2019 Financial Results Release Date and Conference Call Information
Apr 23, 2019
WATERTOWN, Mass. , April 23, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its first quarter ended March 31, 2019 on Wednesday, May 8 .
EyePoint Pharmaceuticals to Present at Upcoming Medical Conferences
Apr 16, 2019
Two Presentations Highlighting YUTIQ™ to be Presented at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Data from Two Phase 3 Studies of DEXYCU ™ to be presented at the 2019 American Society of Cataract and Refractive Surgery (ASCRS) and American Society of
EyePoint Pharmaceuticals to Present at Upcoming Investor Conferences
Apr 02, 2019
WATERTOWN, Mass. , April 02, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that members of the management team are scheduled to present at the
EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Mar 28, 2019
WATERTOWN, Mass. , March 28, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the pricing of an underwritten public offering of 10,526,500 shares
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
Mar 27, 2019
WATERTOWN, Mass. , March 27, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it intends to offer and sell shares of its common stock in an
EyePoint Pharmaceuticals Reports Fiscal Period Ended December 31, 2018 Financial Results and Highlights Recent Clinical and Operational Developments
Mar 14, 2019
-YUTIQ™ and DEXYCU™ commercially launched in 1Q2019- - $60 million debt facility secured to support YUTIQ and DEXYCU commercial launches- -Conference call and webcast today, March 14, at 8:30 a.m. ET- WATERTOWN, Mass. , March 14, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ:
EyePoint Pharmaceuticals Announces U.S. Commercial Launch of DEXYCU (dexamethasone intraocular suspension) 9%
Mar 12, 2019
DEXYCU indicated for the intraocular treatment of postoperative inflammation WATERTOWN, Mass. , March 12, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today
EyePoint Pharmaceuticals Announces Fiscal Period Ended December 31, 2018 Financial Results Release Date and Conference Call Information
Feb 14, 2019
WATERTOWN, Mass. , Feb. 14, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its fiscal period ended December 31, 2018 on Thursday, March
EyePoint Pharmaceuticals Secures Up to $60 Million Debt Facility
Feb 13, 2019
– Provides support for the product launches of YUTIQ™ and DEXYCU™ – WATERTOWN, Mass. , Feb. 13, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced
EyePoint Pharmaceuticals Announces U.S. Commercial Launch of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
Feb 04, 2019
- YUTIQ Indicated for the Treatment of Chronic Non-Infectious Posterior Segment Uveitis - WATERTOWN, Mass. , Feb. 04, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic
EyePoint Pharmaceuticals Appoints David Guyer, M.D., to Board of Directors
Jan 28, 2019
– Dr. Guyer is a Successful Ophthalmology Entrepreneur with Deep Business and Clinical Experience in Advancing Treatments for Ocular Diseases - WATERTOWN, Mass. , Jan. 28, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to
EyePoint Pharmaceuticals Provides 2019 Commercial Update
Jan 03, 2019
- DEXYCU TM commercial launch now expected in 1Q19, earlier than prior guidance of 1H19 - - YUTIQ TM commercial launch on track for 1Q19 -  WATERTOWN, Mass. , Jan. 03, 2019 (GLOBE NEWSWIRE) --   EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing
EyePoint Pharmaceuticals Added to NASDAQ Biotechnology Index
Dec 17, 2018
WATERTOWN, Mass. , Dec. 17, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it has been selected for addition to the NASDAQ Biotechnology Index®
EyePoint Pharmaceuticals Appoints Ron Honig, Esq., as SVP, General Counsel & Company Secretary
Nov 27, 2018
- Industry veteran who brings over 25 years of legal expertise in the medical device industry to newly created position - WATERTOWN, Mass. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and
EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU™ by the Center for Medicare and Medicaid Services (CMS)
Nov 12, 2018
WATERTOWN, Mass. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Centers for Medicare and Medicaid Services (CMS) has assigned
EyePoint Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
Nov 06, 2018
WATERTOWN, Mass. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Officer, is scheduled
EyePoint Pharmaceuticals Reports Fiscal First Quarter 2019 Financial Results and Highlights Recent Clinical and Operational Developments
Nov 06, 2018
-YUTIQ ™ approved by U.S. FDA ; anticipated launch in calendar 1Q19- -Exclusive license granted to Ocumension Therapeutics to develop and commercialize EyePoint’s three-year micro-insert product using the Durasert™ technology for posterior segment uveitis in Greater China - -Commercial preparations
EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert™ Three-Year Treatment for Posterior Segment Uveitis in the Greater China Region
Nov 05, 2018
WATERTOWN, Mass. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension Therapeutics today announced an exclusive license agreement for the
Displaying 21 - 40 of 362
EyePoint Pharmaceuticals